iCAD, TeraRecon ink product licensing and distribution agreement
iCAD Inc. and TeraRecon Inc. this week entered into a three-year product licensing and distribution agreement.
Under the terms of the agreement, TeraRecon said it will develop a new server-based product offering that will include iCAD lung cancer detection, analysis and tracking software in various configurations. The server will be a standalone product to work with existing picture archiving and communication systems (PACS) and DICOM review equipment and other products in the TeraRecon Aquaruis product line.
TeraRecon said that it also has licensed three software modules from iCAD, including: iCAD QuickCue, for automated detection of cancerous lung nodules; iCAD QuickMarch, for automated location, comparison and tracking of cancerous lung nodules in previous or subsequent patient studies; and iCAD QuickChange, which assists in analysis and evaluation of lung cancers by providing quantitative descriptions of lesions based on contrast enhancement studies.
The agreement provides for worldwide distribution through TeraRecon's sales force, independent resellers/distributors and OEM partnerships. The companies also revealed their intention to collaborate and obtain U.S. Food and Drug Administration approvals necessary for distribution in the United States.
TeraRecon said the new product release is anticipated in 2005.
Under the terms of the agreement, TeraRecon said it will develop a new server-based product offering that will include iCAD lung cancer detection, analysis and tracking software in various configurations. The server will be a standalone product to work with existing picture archiving and communication systems (PACS) and DICOM review equipment and other products in the TeraRecon Aquaruis product line.
TeraRecon said that it also has licensed three software modules from iCAD, including: iCAD QuickCue, for automated detection of cancerous lung nodules; iCAD QuickMarch, for automated location, comparison and tracking of cancerous lung nodules in previous or subsequent patient studies; and iCAD QuickChange, which assists in analysis and evaluation of lung cancers by providing quantitative descriptions of lesions based on contrast enhancement studies.
The agreement provides for worldwide distribution through TeraRecon's sales force, independent resellers/distributors and OEM partnerships. The companies also revealed their intention to collaborate and obtain U.S. Food and Drug Administration approvals necessary for distribution in the United States.
TeraRecon said the new product release is anticipated in 2005.